Clinical trial
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium…
NCT00403260 · Medicines for Malaria Venture, Other · Completed
Key facts
| NCT number | NCT00403260 |
|---|---|
| Title | Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients |
| Official title | A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria |
| Lead sponsor | Medicines for Malaria Venture, Other |
| Collaborators | Shin Poong Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Falciparum Malaria |
| Intervention type | Drug |
| Interventions | Pyronaridine - artesunate, Mefloquine plus artesunate |
| Enrollment | 1,271 |
| Start date | Jan 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Nov 23, 2006 |
| Last update posted | Nov 2, 2021 |
| Countries | Burkina Faso, Cambodia, Côte d’Ivoire, India, Tanzania, Thailand, Vietnam |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: